Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial

IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designed for managing presbyopia and enhanced with a proprietary vehicle. OBJECTIVE: To evaluate the efficacy and safety of pilocarpine hydrochloride, 1.25%, in individuals w...

Descripción completa

Detalles Bibliográficos
Autores principales: Waring, George O., Price, Francis W., Wirta, David, McCabe, Cathleen, Moshirfar, Majid, Guo, Qiang, Gore, Anu, Liu, Haixia, Safyan, Eleonora, Robinson, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895317/
https://www.ncbi.nlm.nih.gov/pubmed/35238902
http://dx.doi.org/10.1001/jamaophthalmol.2022.0059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895317/
https://www.ncbi.nlm.nih.gov/pubmed/35238902
http://dx.doi.org/10.1001/jamaophthalmol.2022.0059

Ejemplares similares